Diyabetin Şifresi

Sanders LJ. From Thebes to Toronto and the 21st century: an incredible journey. Diabetes Spectrum. 2002 Jan; 15(1): 56–60. Endnotes 225

Lakhtakia R. The history of diabetes mellitus. Sultan Qaboos Univ Med J. 2013 Aug; 13(3): 368–370.

Karamanou M, et al. Apollinaire Bouchardat (1806–1886): founder of modern Diabetology. Hormones. 2014 Apr-Jun; 13(2): 296–300.

Mazur A. Why were “starvation diets” promoted for diabetes in the pre-insulin period? Nutr J. 2011; 10(1): 23. doi: 10.1186/1475-2891-10-23. Accessed 2017 Jun 6.

Franz, MJ. The history of diabetes nutrition therapy. Diabetes Voice. 2004 Dec; 49: 30–33.

Joslin EP. The treatment of diabetes mellitus. Can Med Assoc J. 1916 Aug; 6(8): 673–684.

Bliss M. The Discovery of Insulin. 2015 Aug 19. Historica Canada. Available from: http://www.thecanadianencyclopedia.ca/en/article/the-discovery-of-insulin/. Accessed 2017 Jun 6.

Furdell EL. Fatal thirst: diabetes in Britain until insulin. Boston: Brill; 2009. p. 147.

Himsworth HP. Diabetes mellitus: its differentiation into insulin-sensitive and insulin-insen- sitive types. Lancet. 1936; 1: 127–130.

Joslin EP. The unknown diabetic. Postgraduate Medicine. 1948; 4(4): 302–306.

US Dept of Health and Human Services and US Dept of Agriculture. Executive summary. 2015–2020 Dietary guidelines for Americans. Available from: http://health.gov/dietarygui- delines/2015/guidelines/executive-summary/. Accessed 2017 Jun 6.

Siri-Tarino PW, et al. Meta-analysis of prospective cohort studies evaluating the associati- on of saturated fat with cardiovascular disease. Am J Clin Nutr. 2010; 91(3): 535–546, doi: 10.3945/ajcn.2009.27725. Accessed 2017 Jun 6.; Mente A, et al. A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease. Arch Intern Med. 2009; 169(7): 659–669. 13. Centers for Disease Control and Prevention. Prevalence of overweight, obesity, and extreme obesity among adults: United States, tren- ds 1960–1962 through 2007–2008. 2011 Jun 6. Available from: http://www.cdc.gov/nchs/data/hestat/obesity_adult_07_08/obesity_adult_07_08.htm. Accessed 2015 Apr 26. Used with permission.

World Health Organization. Global report on diabetes. 2016. Available from: http://apps. who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf. Accessed 2017 Jun 6.

Pinhas-Hamiel O, Zeitler P. The global spread of type 2 diabetes mellitus in children and ado- lescents. J Pediatr. 2005; 146(5): 693–700. doi: 10.1016/j.jpeds.2004. 12.042. Accessed 2017 Jun 6.

Centers for Disease Control and Prevention. Number (in Millions) of Civilian, Non-Institutio- nalized Persons with Diagnosed Diabetes, United States, 1980-2014. Available from: https:// www.cdc.gov/diabetes/statistics/prev/national/figpersons. htm. Accessed 2017 Jun 6. Used with permission.

Tabish SA. Is diabetes becoming the biggest epidemic of the twenty-first century? Int J Health Sci. 2007; 1(2): 5–8.

Xu Y, et al. Prevalence and control of diabetes in Chinese adults. JAMA. 2013; 310(9): 948– 958.

International Diabetes Federation. IDF diabetes atlas, 7th edition. 2015. p. 14. Available from: www.idf.org/diabetesatlas. Accessed 2017 Jan 15.

Menke A, et al. Prevalence of and trends in diabetes among adults in the United States, 1988– 2012. JAMA. 2015; 314(10): 1021–1029.

Polonsky KS. The past 200 years in diabetes. N Engl J Med 2012; 367(14): 1332–1340.

American Diabetes Association. Standards of medical care in diabetes—2016. Diabetes Care. 2016; 39(Suppl. 1): S13–S22.

Zhang X, et al. A1C level and future risk of diabetes: a systematic review. Diabetes Care. 2010; 33(7): 1665–1673.

Van Bell TL, et al. Type 1 diabetes: etiology, immunology, and therapeutic strategies.Phys Rev 2011; 91(1): 79–118.

Joslin’s diabetes mellitus, 14th edition. Boston: Lippincott Williams & Wilkins; 2005. p. 399.

Type 1 diabetes. New York Times. 2014 July 21. Available from: http://www. nytimes.com/ health/guides/disease/type-1-diabetes/complications.html. Accessed 2017 Jun 6.

Rosenbloom AL, et al. Type 2 diabetes in children and adolescents. Pediatr Diabetes 2009; 10(Suppl. 12): 17–32.

Haines L, et al. Rising incidence of type 2 diabetes in children in the U.K. Diabetes Care. 2007; 30(5): 1097–1101.

Grinstein G, et al. Presentation and 5-year follow-up of type 2 diabetes mellitus in African-A- merican and Caribbean-Hispanic adolescents. Horm Res 2003; 60(3): 121–126.

Pinhas-Hamiel O, Zeitler P. The global spread of type 2 diabetes mellitus in children and ado- lescents. J Pediatr. 2005; 146(5): 693–700. doi: 10.1016/j.jpeds.2004.12.042. Accessed 2017 Jun 6.

U.S. Department of Health and Human Services. National Diabetes Fact Sheet,2011. Available from: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf.Accessed 2017 Jun 6.

Fong DS, et al. Diabetic retinopathy. Diabetes Care. 2004; 27(10): 2540–2553.

Keenan HA, et al. Clinical factors associated with resistance to microvascular complications in diabetic patients of extreme disease duration: the 50-year medalist study. Diabetes Care. 2007; 30(8):1995–1997.

National Institute of Diabetes and Digestive and Kidney Diseases. Diabetic kidney disease. 2016 Jul. Available from: http://www.niddk.nih.gov/health-information/health-topics/kid- ney-disease/kidney-disease-of-diabetes/Pages/facts.aspx.Accessed 2017 Jun 6.

National Institute of Diabetes and Digestive and Kidney Diseases. Adjusted prevalence rates of ESRD. Available from: http://www.niddk.nih.gov/healthinformation/health-statistics/ Pages/kidney-disease-statistics-united-states.aspx. Accessed 2017 Jun 6. Used with permis- sion.

Adler AI, et al. Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63(1): 225–232.

National Institute of Diabetes and Digestive and Kidney Diseases. Nerve damage(diabetic neuropathies). 2013 Nov. Available from: http://www.niddk.nih.gov/health-information/ health-topics/Diabetes/diabetic-neuropathies-nerve-damagediabetes/Pages/diabeti- c-neuropathies-nerve-damage.aspx. Accessed 2017 Jun 6.

Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes.2008; 26(2): 77–82.

Boulton AJ, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care. 2005; 28(4): 956–962.

Maser RE, et al. The association between cardiovascular autonomic neuropathy and morta- lity in individuals with diabetes: a meta-analysis. Diabetes Care. 2003;26(6): 1895–1901.

Kannel WB, et al. Diabetes and cardiovascular disease: the Framingham study. JAMA. 1979; 241(19): 2035–2038.

American Heart Association. Cardiovascular disease & diabetes. 2015 Aug.Available from: http://www.heart.org/HEARTORG /Conditions/More/Diabetes/WhyDiabetesMatters/Car- diovascular-Disease-Diabetes_UCM_313865_Article.jsp/#.WZYRWK3MxE4. Accessed 2017 Jun 6.

Gu K, et al. Diabetes and decline in heart disease mortality in U.S. adults. JAMA. 1999; 281(14): 1291–1297.

Beckman JA, et al. Diabetes and atherosclerosis: epidemiology, pathophysiology and manage- ment. JAMA. 2002; 287(19): 2570–2581.

Air EL, Kissela BM. Diabetes, the metabolic syndrome, and ischemic stroke: epidemiology and possible mechanisms. Diabetes Care. 2007; 30(12): 3131–3140.

Banerjee C, et al. Duration of diabetes and risk of ischemic stroke: the Northern Manhattan Study. Stroke. 2012 May; 43(5): 1212–1217.

American Diabetes Association. Peripheral arterial disease in people with diabetes. Diabetes Care. 2003; 26(12): 3333–3341.

2016 Alzheimer’s disease facts and figures. Available from: http://www.alz.org/facts/. Ac- cessed 2017 Feb 17.

De la Monte SM, Wands JR. Alzheimer’s disease is type 3 diabetes—evidencereviewed. J Dia- betes Sci Technol. 2008 Nov; 2(6): 1101–1113.

Barone BB, et al. Long-term all-cause mortality in cancer patients with preexistingdiabetes mellitus: a systematic review and meta-analysis. JAMA. 2008 Dec 17;300(23): 2754–2764.

Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015 Jun 9;313(22): 2263–2273.

Ludwig E. [Urinary tract infections in diabetes mellitus.] Orv Hetil. 2008 Mar 30;149(13): 597–600.

Pemayun TGD, et al. Risk factors for lower extremity amputation in patients with diabetic foot ulcers: a hospital-based case–control study. Diabetic Foot & Ankle. 2015; 6(1). doi: 10.3402/dfa.v6.29629. Accessed 2017 Jun 6.

Kahana M, et al. Skin tags: a cutaneous marker for diabetes mellitus. Acta Derm Venereol. 1987; 67(2): 175–177.

Lakin M, Wood H. Erectile dysfunction. Cleveland Clinic Center for Continuing Education. 2012 Nov. Available from: http://www.clevelandclinicmeded.com/medicalpubs/diseasema- nagement/endocrinology/erectile-dysfunction/. Accessed 2017 Feb 17.

Sharpless JL. Polycystic ovary syndrome and the metabolic syndrome. Clinical Diabetes.2003 Oct; 21(4): 154–161.

Colditz GA, et al. Weight as a risk factor for clinical diabetes in women. Am J Epidemiol.1990 Sep; 132(3): 501–513.

Powell A. Obesity? diabetes? we’ve been set up. Harvard Gazette. 2012 Mar 7.Available from: http://news.harvard.edu/gazette/story/2012/03/the-big-setup/. Accessed 2017 Jun 6.

Colditz GA, et al. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med. 1995 Apr 1; 122(7): 481–486.

Tobias DK, et al. Body-mass index and mortality among adults with incident type 2 diabetes. N Engl J Med. 2014; 370(3): 233–244.

Hu FB, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med. 2001; 345(11): 790–797.

Harcombe Z, et al. Evidence from randomised controlled trials did not support the introduc- tion of dietary fat guidelines in 1977 and 1983: a systematic review and meta-analysis. Open Heart. 2015; 2(1): e000196. doi: 10.1136/ openhrt-2014-000196. Accessed 2017 Jun 6.

Wei M, et al. Waist circumference as the best predictor of noninsulin dependent diabetes mellitus (NIDDM) compared to body mass index, waist/hip ratio and other anthropometric measurements in Mexican Americans—a 7-year prospective study. Obes Res. 1997 Jan; 5(1): 16–23.

McSweeny L. The devil inside. The Sydney Morning Herald. 2013 Sept 15. Available from: http://www.smh.com.au/lifestyle/the-devil-inside-20130910-2thyr.html. Accessed 2017 Jun 6.

Wildman RP. Healthy obesity. Curr Opin Clin Nutr Metab Care. 2009; 12(4): 438–443.

Ruderman N, et al. The metabolically obese, normal-weight individual revisited. Diabetes. 1998; 47(5): 699–713. 11. Taylor R, Holman RR. Normal-weight individuals who develop type 2 diabetes: the personal fat threshold. Clinical Science. 2015 Apr; 128(7): 405–410.

Després JP. Is visceral obesity the cause of the metabolic syndrome? Ann Med. 2006; 38(1): 52–63.

Taylor R, Holman RR. Normal-weight individuals who develop type 2 diabetes: the personal fat threshold. Clinical Science. 2015 Apr; 128(7): 405–410. Used with permission.

Matos LN, et al. Correlation of anthropometric indicators for identifying insulin sensitivity and resistance. Sao Paulo Med J. 2011; 129(1): 30–35.

Rexrode KM, et al. Abdominal adiposity and coronary heart disease in women. JAMA. 1998; 280(21): 1843–1848.

Wander PL, et al. Change in visceral adiposity independently predicts a greater risk of de- veloping type 2 diabetes over 10 years in Japanese Americans. Diabetes Care. 2013; 36(2): 289–293.

Fujimoto WY, et al. Body size and shape changes and the risk of diabetes in the diabetes pre- vention program. Diabetes. 2007 Jun; 56(6): 1680–1685.

Klein S, et al. Absence of an effect of liposuction on insulin action and risk factors for coro- nary heart disease. N Engl J Med. 2004; 350(25): 2549–2557.

Ashwell M, et al. Waist-to-height ratio is more predictive of years of life lost than body mass index. PLoS One. 2014; 9(9): e103483. doi: 10.1371/journal. pone.0103483. Accessed 2017 Jun 6.

Ashwell M, et al. Waist-to-height ratio is more predictive of years of life lost than body mass index. PLoS One. 2014; 9(9): e103483. doi: 10.1371/journal. pone.0103483. Accessed 2017 Jun 6. Used with permission.

Bray GA, et al. Relation of central adiposity and body mass index to the development of diabe- tes in the Diabetes Prevention Program. Am J Clin Nutr. 2008; 87(5): 1212–1218; Fox CS, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with meta- bolic risk factors in the Framingham Heart Study. Circulation. 2007; 116(1): 39–48; Després JP. Intra-abdominal obesity: an untreated risk factor for type 2 diabetes and cardiovascular disease. J Endocrinol Invest. 2006; 2(3 Suppl): 77–82; Jakobsen MU, et al. Abdominal obesity and fatty liver. Epidemiol Rev. 2007; 29(1): 77–87.

Fabbrini E, Tamboli RA, et al. Surgical removal of omental fat does not improve insulin sensi- tivity and cardiovascular risk factors in obese adults. Gastroenterology. 2010; 139(2): 448– 455.

Fabbrini E, et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA. 2009; 106(36): 15430–15435; Magkos F, Fabbrini E, et al. Increased whole-body adiposity without a concomitant increase in liver fat is not associated with augmented metabolic dysfunction. Obesity (Silver Spring). 2010; 18(8): 1510–1515.

Jakobsen MU, et al. Abdominal obesity and fatty liver. Epidemiol Rev. 2007; 29(1):77–87.

Howard BV, et al. Low-fat dietary pattern and weight change over 7 years: theWomen’s He- alth Initiative Dietary Modification Trial. JAMA. 2006 Jan 4; 295(1):39–49.

Fildes A, et al. Probability of an obese person attaining normal body weight: cohort study using electronic health records. Am J Public Health. 2015; 105(9): e54–e59.

1. Banting W. Letter on Corpulence. Available from: http://www.thefitblog.net/ebooks/Lette- rOnCorpulence/LetteronCorpulence.pdf. Accessed 2017 Jun 6.

Pories WJ, et al. Surgical treatment of obesity and its effect on diabetes: 10-y follow-up. Am J Clin Nutr. 1992; 55(Suppl.): 582S–585S.

Based on data from Pories WJ, et al. Surgical treatment of obesity and its effect ondiabetes: 10-y follow-up. Am J Clin Nutr. 1992 Feb; 55(2 Suppl): 582S–585S.

Insulinoma symptoms. Insulinoma Support Network. Available from: https://insulinoma. co.uk/insulinoma-symptoms. Accessed 2017 Jun 6.

Tarchouli M, et al. Long-standing insulinoma: two case reports and review of the literature. BMC Res Notes. 2015; 8: 444.

Ghosh S, et al. Clearance of acanthosis nigricans associated with insulinoma following surgi- cal resection. QJM. 2008 Nov; 101(11): 899–900. doi: 10.1093/qjmed/hcn098. [Epub 2008 Jul 31.] Accessed 2017 Jun 6.

Rizza RA. Production of insulin resistance by hyperinsulinemia in man. Diabetologia.1985; 28(2): 70–75.

Del Prato S. Effect of sustained physiologic hyperinsulinemia and hyperglycemia on insulin secretion and insulin sensitivity in man. Diabetologia. 1994 Oct; 37(10):1025–1035.

Henry RR. Intensive conventional insulin therapy for type II diabetes. Diabetes Care. 1993; 16(1): 23–31.

Corkey BE, Banting lecture 2011: hyperinsulinemia: cause or consequence? Diabetes. 2012 Jan; 61(1): 4–13.

Based on data from Tabák AG, et al. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet. 2009 Jun 27; 373(2682): 2215–2221.

Tabák AG, et al. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet. 2009 Jun 27; 373(2682): 2215–2221.

Weiss R, Taksali SE, et al. Predictors of changes in glucose tolerance status in obese youth. Diabetes Care. 2005; 28(4): 902–909.

Taksali SE, et al. High visceral and low abdominal subcutaneous fat stores in the obese ado- lescent: a determinant of an adverse metabolic phenotype. Diabetes. 2008; 57(2): 367–371.

Bawden S, et al. Increased liver fat and glycogen stores following high compared with low glycaemic index food: a randomized crossover study. Diabetes Obes Metab. 2017 Jan; 19(1): 70–77. doi: 10.1111/dom.12784. [Epub 2016 Sep 4]. Accessed 2017 Jun 6.

Suzuki A, et al. Chronological development of elevated aminotransferases in a non-alcoholic population. Hepatology. 2005; 41(1): 64–71.

Zelman S. The liver in obesity. AMA Arch Intern Med. 1952; 90(2): 141–156. 8. Ludwig J, et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980 Jul; 55(7): 434–438.

Leite NC, et al. Prevalence and associated factors of non-alcoholic fatty liver disease in pa- tients with type-2 diabetes mellitus. Liver Int. 2009 Jan; 29(1): 113–119.

Seppala-Lindroos A, et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in nor- mal men. J Clin Endocrinol Metab. 2002 Jul; 87(7): 3023–3028.

Silverman JF, et al. Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol. 1990; 85(10): 1349–1355.

Fraser A, et al. Prevalence of elevated alanine-aminotransferase (ALT ) among US adolescents and associated factors: NHANES 1999–2004. Gastroenterology. 2007; 133(6): 1814–1820.

Fabbrini E, et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA 2009; 106(36): 15430–15435; D’Adamo E, Caprio S. Type 2 diabetes in youth: epidemiology and pathophysiology. Diabetes Care. 2011; 34(Suppl 2): S161–S165.

Burgert TS, et al. Alanine aminotransferase levels and fatty liver in childhood obesity: asso- ciations with insulin resistance, adiponectin, and visceral fat. J Clin Endocrinol Metab. 2006; 91(11): 4287–4294.

Younossi AM, et al. Systematic review with meta-analysis: non-alcoholic steatohepatitis. Ali- ment Pharmacol Ther. 2014; 39(1): 3–14.

Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002; 346(16): 1221–1231.

Based on data from D’Adamo E, Caprio S. Type 2 diabetes in youth: epidemiology and pathop- hysiology. Diabetes Care. 2011 May; 34(Suppl 2): S161-S165.

Ryysy L, et al. Hepatic fat content and insulin action on free fatty acids and glucose metabo- lism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes. 2000; 49(5): 749–758; 18.

Sevastianova K, et al. Effect of short-term carbohydrate overfeeding and longterm weight loss on liver fat in overweight humans. Am J Clin Nutr. 2012; 96(4): 727–734.

Schwarz JM, et al. Short-term alterations in carbohydrate energy intake in humans. Striking effects on hepatic glucose production, de novo lipogenesis, lipolysis, and whole-body fuel selection. J Clin Invest. 1995; 96(6): 2735–2743; Softic S, et al. Role of dietary fructose and hepatic de novo lipogenesis in fatty liver disease. Dig Dis Sci. 2016 May; 61(5): 1282–1293.

Chong MF, et al. Mechanisms for the acute effect of fructose on postprandial lipemia. Am J Clin Nutr. 2007; 85(6): 1511–1520.

Perseghin G. Reduced intrahepatic fat content is associated with increased wholebody lipid oxidation in patients with type 1 diabetes. Diabetologia. 2005; 48(12): 2615–2621.

Fabbrini E, et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA 2009; 106(36): 15430–15435.

Weiss R, Dufour S, et al. Pre-diabetes in obese youth: a syndrome of impaired glucose toleran- ce, severe insulin resistance, and altered myocellular and abdominal fat partitioning. Lancet. 2003; 362(9388): 951–957.

Kelley DE, et al. Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity and weight loss. Am. J. Physiol Endocrinol Metab. 1999; 277(6 Pt 1): E1130–E1141.

Hue L, Taegtmeyer H. The Randle cycle revisited: a new head for an old hat. Am J Physiol Endocrinol Metab. 2009 Sep; 297(3): E578–E591.

Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009; 58(4): 773–795.

Taylor R. Type 2 diabetes: etiology and reversibility. Diabetes Care. 2013; 36(4):1047–1055.

Mathur A, et al. Nonalcoholic fatty pancreas disease. HPB. 2007; 9(4): 312–318; Lee JS, et al. Clinical implications of fatty pancreas: Correlations between fatty pancreas and metabolic syndrome. World J Gastroenterol. 2009; 15(15): 1869–1875.

Ou HY, et al. The association between nonalcoholic fatty pancreas disease and diabetes. PLoS One. 2013; 8(5): e62561.

Steven S, et al. Weight loss decreases excess pancreatic triacylglycerol specifically in type 2 diabetes. Diabetes Care. 2016; 39(1): 158-165.

Heni M, et al. Pancreatic fat is negatively associated with insulin secretion in individuals with impaired fasting glucose and/or impaired glucose tolerance: a nuclear magnetic resonance study. Diabetes Metab Res Rev. 2010 Mar; 26(3): 200–205. doi: 10.1002/dmrr.1073; Tushu- izen ME, et al. Pancreatic fat content and beta-cell function in men with and without type 2 diabetes. Diabetes Care. 2007; 30(11): 2916–2921.

Klein S, et al. Absence of an effect of liposuction on insulin action and risk factors for coro- nary heart disease. N Engl J Med. 2004; 350(25): 2549–2557.

Lim EL, et al. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia. 2011; 54(10): 2506–2514.

Kim JY, et al. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J. Clin. Invest. 2007; 117(9): 2621–2637.

Rasouli N, et al. Ectopic fat accumulation and metabolic syndrome. Diabetes Obes Metab. 2007; 9(1): 1–10.

Vague J. The degree of masculine differentiation of obesities: a factor determining predispo- sition to diabetes, atherosclerosis, gout and uric calculous disease. Am J Clin Nutr. 1956; 4(1): 20–34.

Cao W, et al. Excess exposure to insulin is the primary cause of insulin resistance and its as- sociated atherosclerosis. Curr Mol Pharmacol. 2011; 4(3): 154–166.

Lustig, R. Sugar: the bitter truth. YouTube. Available from: https://www.youtube. com/wat- ch?v=dBnniua6-oM. Accessed 2017 Jun 6.

Yudkin J. Pure, White and Deadly. London: HarperCollins; 1972.

Basu S, et al. The relationship of sugar to population-level diabetes prevalence: an economet- ric analysis of repeated cross-sectional data. PLoS One. 2013; 8(2):e57873.

Ridgeway, L. High fructose corn syrup linked to diabetes. USC News. 2012 Nov 28. Available from: https://news.usc.edu/44415/high-fructose-corn-syrup-linked-todiabetes/. Accessed 2017 Jun 6.

Bizeau ME, Pagliassotti MJ. Hepatic adaptations to sucrose and fructose. Metabolism. 2005; 54(9): 1189–1201.

Faeh D, et al. Effect of fructose overfeeding and fish oil administration on hepatic de novo lipogenesis and insulin sensitivity in healthy men. Diabetes. 2005; 54(7): 1907–1913.

Lustig RH. Fructose: metabolic, hedonic, and societal parallels with ethanol. J AmDiet Assoc. 2010; 110(9): 1307–1321.

Yokoyama H, et al. Effects of excessive ethanol consumption on the diagnosis of the metabolic syndrome using its clinical diagnostic criteria. Intern Med. 2007;46(17): 1345–1352.

Beck-Nielsen H, et al. Impaired cellular insulin binding and insulin sensitivity induced by high-fructose feeding in normal subjects. Am J Clin Nutr. 1980 Feb; 33(2): 273–278.

Stanhope KL, et al. Consuming fructose-sweetened, not glucose-sweetened, beverages inc- reases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. JCI. 2009; 119(5): 1322–1334.

Xu Y, et al. Prevalence and control of diabetes in Chinese adults. JAMA. 2013; 310(9): 948– 959.

Zhou BF, et al. Nutrient intakes of middle-aged men and women in China, Japan, United King- dom, and United States in the late 1990s: the INTERMAP study. J Hum Hypertens. (2003); 17(9): 623–630. doi: 10.1038/sj.jhh.1001605.

Based on data from Zhou BF, et al. Nutrient intakes of middle-aged men and women in China, Japan, United Kingdom, and United States in the late 1990s: the INTERMAP study. J Hum Hypertens. 2003 Sept; 17(9): 623–630. doi: 10.1038/sj. jhh.1001605. Accessed 2017 Jun 6.

Gross LS, et al. Increased consumption of refined carbohydrates and the epidemic of type 2 diabetes in the United States: an ecologic assessment. Am J Clin Nutr. 2004; 79(5): 774–779.

Basu S, et al. The relationship of sugar to population-level diabetes prevalence: an economet- ric analysis of repeated cross-sectional data. PLoS One. 2013; 8(2): e57873. doi: 10.1371/ journal.pone.0057873. Accessed 2015 Apr 8.

Malik VS, et al. Sugar-sweetened beverages and risk of metabolic syndrome and type 2 diabe- tes. Diabetes Care. 2010; 33(11): 2477–2483.

Goran MI, et al. High fructose corn syrup and diabetes prevalence: A global perspective. Glob Pub Health. 2013; 8(1): 55–64.

Gross LS, et al. Increased consumption of carbohydrates and the epidemic of type 2 diabetes in the United States: an ecologic assessment. Am J Clin Nutr. 2004 May;79(5): 774–779. Used with permission.

Grundy SM, et al. Diagnosis and management of the metabolic syndrome: anAmerican Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005 Oct 25; 112(17): 2735–2752.

Ginsberg HN, MacCallum PR. The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. Cardio- metab Syndr. 2009 Spring; 4(2): 113–119.

Bremer AA, et al. Toward a unifying hypothesis of metabolic syndrome. Pediatrics. 2012; 129(3): 557–570.

Reaven GM. Banting lecture, 1988. Role of insulin resistance in human disease. Diabetes. 1988; 37(12): 1595–1607.

Ahrens EH, et al. Carbohydrate-induced and fat-induced lipemia. Trans. Assoc. Am. Phys. 1961; 74: 134–146.

Reaven GM, Calciano A, et al. Carbohydrate intolerance and hyperlipemia in patients with myocardial infarction without known diabetes mellitus. J Clin Endocrinol Metab. 1963; 23: 1013–1023.

Welborn TA, et al. Serum-insulin in essential hypertension and in peripheral vascular disea- se. Lancet. 1966; 1(7451): 1336–1337.

Lucas CP, et al. Insulin and blood pressure in obesity. Hypertension. 1985; 7: 702–706.

Huang PL. A comprehensive definition for metabolic syndrome. Dis Model Mech. 2009 May– Jun; 2(5–6): 231–237.

Reaven GM, et al. Insulin resistance as a predictor of age-related diseases. J Clin Endocrinol Metab. 2001; 86(8): 3574–3578; DeFronzo RA, Ferrannini E. Insulin resistance. A multiface- ted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclero- tic cardiovascular disease. Diabetes Care. 1991;14 (3): 173–194.

Lim JS, et al. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol. 2010; 7(5): 251–264.

Grundy SM, et al. Transport of very low density lipoprotein triglycerides in varying degrees of obesity and hypertriglyceridemia. J. Clin. Invest. 1979; 63: 1274–1283.

Adiels M, et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia. 2006; 49(4): 755–765.

Aarsland A, et al. Contributions of de novo synthesis of fatty acids to total VLDL-triglyceride secretion during prolonged hyperglycemia/hyperinsulinemia in normal man. J Clin Invest. 1996; 98(9): 2008–2017.

Hiukka A, et al. Alterations of lipids and apolipoprotein CIII in VLDL subspecies in type 2 diabetes. Diabetologia. 2005; 48(6): 1207–1215; Grundy SM, et al. Transport of very low density lipoprotein triglycerides in varying degrees of obesity and hypertriglyceridemia. J. Clin. Invest. 1979; 63: 1274–1283.

Coulston AM, et al. Persistence of hypertriglyceridemic effects of low-fat, high-carbohydrate diets in NIDDM. Diabetes Care. 1989; 12(2): 94–100; Hyson DA, et al. Impact of dietary fat in- take on postprandial lipemic response in postmenopausal women. FA SEB J. 1999; 13: A213.

Reaven GM, et al. Role of insulin in endogenous hypertriglyceridemia. J Clin Invest. 1967; 46(11): 1756–1767; Stanhope KL, et al. Consumption of fructose and high fructose corn sy- rup increase postprandial triglycerides, LDL-cholesterol, and apolipoprotein-B in young men and women. J Clin Endocrinol Metab. 2011 Oct; 96(10): E1596–E1605.

Nordestgaard BG, et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007; 298(3): 299–308.

Schwarz GG, et al. Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins. J Am Coll Cardiol. 2015; 65(21): 2267–2275.

Miller M, et al. Triglycerides and cardiovascular disease: A scientific statement from the Ame- rican Heart Association. Circulation. 2011; 123(20): 2292–2333.

HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014; 371(3): 203–212; AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2012; 365(24): 2255–2267.

Vergeer M, et al. The HDL hypothesis: does high-density lipoprotein protect from atheroscle- rosis? J Lipid Res. 2010 Aug; 51(8): 2058–2073.

Finelli C, et al. The improvement of large high-density lipoprotein (HDL) particle levels, and presumably HDL metabolism, depend on effect of low-carbohydrate diet and weight loss. EXCL I Journal. 2016; 15: 166–176.

ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007; 357(21): 2109–2122.

Ginsberg HN, et al. Regulation of plasma triglycerides in insulin resistance and diabetes. Arch Med Res. 2005; 36(3): 232–240.

Goodpaster BH, et al. Obesity, regional body fat distribution, and the metabolic syndrome in older men and women. Arch Intern Med. 2005; 165(7): 777–783.

Barzilai N, et al. Surgical removal of visceral fat reverses hepatic insulin resistance. Diabe- tes. 1999; 48(1): 94–98; Gabriely I, et al. Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: an adipokine-mediated process? Diabetes. 2002; 51(10): 2951–2958.

Klein S, et al. Absence of an effect of liposuction on insulin action and risk factors for coro- nary heart disease. N Engl J Med. 2004; 350(25): 2549–2557.

Welborn T, et al. Serum-insulin in essential hypertension and in peripheral vascular disease. Lancet. 1966; 1(7451): 1336–1337.

Ferrannini E, et al. Insulin resistance, hyperinsulinemia, and blood pressure. Role of age and obesity. Hypertension. 1997; 30(5): 1144–1149.

Park SE, et al. Impact of hyperinsulinemia on the development of hypertension in normoten- sive, nondiabetic adults: a 4-year follow-up study. Metabolism. 2013 Apr; 62(4): 532–538.

Xun P, et al. Fasting insulin concentrations and incidence of hypertension, stroke, and co- ronary heart disease: a meta-analysis of prospective cohort studies. Am J Clin Nutr. 2013; 98(6): 1543–1554.

Christlieb R, et al. Is insulin the link between hypertension and obesity? Hypertension.1985; 7(Suppl II): II-54–II-57; Cao W, et al. Excess exposure to insulin is the primary cause of insu- lin resistance and its associated atherosclerosis. Curr Mol Pharmacol. 2011; 4(3): 154–166.

Rieker RP, et al. Positive inotropic action of insulin on piglet heart. Yale. J. Biol. Med., 1975; 48: 353–360.

Bönner G. Hyperinsulinemia, insulin resistance, and hypertension. J Cardiovasc Pharmacol. 1994; 24(Suppl 2): S39–49.

Sattar N, et al. Serial metabolic measurements and conversion to type 2 diabetes in the West of Scotland Coronary Prevention Study. Diabetes. 2007; 56(4): 984–991.

Kolata G. Skinny and 119 pounds, but with the health hallmarks of obesity. New York Times. 2016 July 22. Available from: https://www.nytimes.com/2016/07/26/health/skinny-fat. html?mcubz=3

Geller AI, et al. National estimates of insulin-related hypoglycemia and errors leading to emergency department visits and hospitalizations. JAMA Intern Med. 2014 May; 174(5): 678–686.

The Diabetes Control and Complications Trial Research Group. The effect of intensive tre- atment of diabetes on the development and progression of longterm complications in insu- lin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14): 977–986.

The DCCT/EDIC Study Research Group. Intensive diabetes treatment and cardiovascular di- sease in patients with type 1 diabetes. N Engl J Med. 2005; 353(25): 2643–2653.

Based on data from The Diabetes Control and Complications Trial Research Group. Influ- ence of intensive diabetes treatment on body weight and composition of adults with type 1 diabetes in the Diabetes Control and Complications Trial. Diabetes Care. 2001 Oct; 24(10): 1711–1721.

Purnell JQ, et al. The effect of excess weight gain with intensive diabetes treatment on cardio- vascular disease risk factors and atherosclerosis in type 1 diabetes: Results from the Diabetes Control and Complications Trial / Epidemiology of Diabetes Interventions and Complicati- ons Study (DCCT/EDIC) study. Circulation. 2013 January 15; 127(2): 180–187. doi: 10.1161/ CIRCULAT IONAHA.111.077487. Accessed 2017 Jun 6.

Muis MJ. High cumulative insulin exposure: a risk factor of atherosclerosis in type 1 diabetes? Atherosclerosis. 2005 Jul; 181(1): 185–192.

UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulp- honylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998 Sep 12; 352(9131): 837-53.

UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose ontrol with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998 Sep 12; 352(9131): 854-865.

Rosen CL, et al. The rosiglitazone story—lessons from an FDA Advisory Committee Meeting. N Engl J Med. 2007; 357(9): 844–846.

The ACCOR D Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008 Jun 12; 358(24): 2545–2559.

The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358(24): 2560–2572.

Duckworth W, et al. Glucose control and vascular complications in veterans with type 2 dia- betes. N Engl J Med. 2009; 360(2): 129–139.

The OR IGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dy- sglycemia. N Engl J Med. 2012; 367(4): 319–328.

The ACCOR D Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcome. N Engl J Med. 2011; 364(9): 818–828; Hayward RA, et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015; 372(23): 2197– 2206; Zoungas S, et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med. 2014; 371(15): 1392–1406.

King P, et al. The UK Prospective Diabetes Study (UKPDS): clinical and therapeutic implicati- ons for type 2 diabetes. Br J Clin Pharmacol. 1999; 48(5): 643–648.

Soedamah-Muthu SS, et al. Relationship between risk factors and mortality in type 1 diabetic patients in Europe. The EURO DIAB Prospective Complications Study (PCS). Diabetes Care. 2008; 31(7): 1360–1366.

Bain SC, et al. Characteristics of type 1 diabetes of over 50 years duration (the Golden Years Cohort). Diabetic Medicine. 2003; 20(10): 808–811.

Crofts CAP, et al. Hyperinsulinemia: a unifying theory of chronic disease? Diabesity. 2015; 1(4): 34–43; 41. Meinert CL, et al. A study of the effects of hypoglycemic agents on vascu- lar complications in patients with adult-onset diabetes. II. Mortality results. Diabetes. 1970; 19(Suppl): 789–830.

Yudkin JS, et al. Intensified glucose lowering in type 2 diabetes: time for a reappraisal. Diabe- tologia. 2010 Oct; 53(10): 2079–2085.

Pradhan AD, et al. Effects of initiating insulin and metformin on glycemic control and inflam- matory biomarkers among patients with type 2 diabetes The LA NCET Randomized Trial. JAMA. 2009; 302(11): 1186–1194; Ridker PM, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000; 342(12): 836–843.

Haffner SM, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med, 1998; 339(4): 229–234.

Madonna R, De Caterina R. Prolonged exposure to high insulin impairs the endothelial PI3-kinase/Akt/nitric oxide signalling. Thromb Haemost. 2009; 101(2): 345–350; Okouc- hi M, et al. High insulin enhances neutrophil transendothelial migration through increasing surface expression of platelet endothelial cell adhesion molecule-1 via activation of mitogen activated protein kinase. Diabetologia. 2002; 45(10): 1449–1456; Pfeifle B, Ditschuneit H. Ef- fect of insulin on growth of cultured human arterial smooth muscle cells. Diabetologia. 1981; 20(2): 155–158; Stout RW, et al. Effect of insulin on the proliferation of cultured primate arterial smooth muscle cells. Circ Res. 1975; 36: 319–327; Iida KT, et al. Insulin up-regulates tumor necrosis factor-alpha production in macrophages through an extracellular-regulated kinase-dependent pathway. J Biol Chem. 2001; 276(35): 32531–32537.

Rensing KL. Endothelial insulin receptor expression in human atherosclerotic plaques: lin- king micro- and macrovascular disease in diabetes? Atherosclerosis. 2012; 222(1): 208–215.

Duff GL, McMillan GC. The effect of alloxan diabetes on experimental cholesterol atheroscle- rosis in the rabbit. J. Exp. Med. 1949; 89(6): 611–630.

Selvin E. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med. 2010; 362(9): 800–811.

Currie CJ, Poole CD, et al. Mortality and other important diabetes-related outcomes with in- sulin vs other antihyperglycemic therapies in type 2 diabetes. J Clin Endocrinol Metab. 2013; 98(2): 668–677.

Roumie CL, et al. Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabe- tes. JAMA. 2014 Jun 11; 311(22): 2288–2296.

Currie CJ, Peters JR, et al. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet. 2010; 375(9713): 481–489.

Based on data from Gamble JM, et al. Insulin use and increased risk of mortality in type 2 diabetes. Diabetes, Obes Metab. 2010 Jan; 12(1): 47–53.

Després JP, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl. J. Med. 1996; 334(15): 952–957.

Gamble JM, et al. Insulin use and increased risk of mortality in type 2 diabetes: a cohort study. Diabetes Obes Metab. 2010; 12(1): 47–53.

Margolis DJ, et al. Association between serious ischemic cardiac outcomes and medications used to treat diabetes. Pharmacoepidemiol Drug Saf. 2008 Aug; 17(8): 753–759.

Colayco DC, et al. A1C and cardiovascular outcomes in type 2 diabetes. Diabetes Care. 2011; 34(1): 77–83; In T2DM, lower HbA1c associated with elevated mortality risk vs moderate HbA1c | ADA. Univadis. 2016 Jun 13. Available from: http://www. univadis.com/viewartic- le/in-t2dm-lower-hba1c-associated-with-elevated-mortality- risk-vs-moderate-hba1c-a- da-414150. Accessed 2017 Jun 6.

Stoekenbroek RM, et al. High daily insulin exposure in patients with type 2 diabetes is as- sociated with increased risk of cardiovascular events. Atherosclerosis. 2015 Jun; 240(2): 318–323.

Smooke S, et al. Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am Heart J. 2005 Jan; 149(1): 168–174.

Johnson JA, Carstensen B, et al. Diabetes and cancer: evaluating the temporal relationship between type 2 diabetes and cancer incidence. Diabetologia. 2012; 55(6): 1607–1618.

Johnson JA, Gale EAM, et al. Diabetes, insulin use, and cancer risk: are observational studies part of the solution—or part of the problem? Diabetes. 2010 May; 59(5): 1129–1131.

Gunter MJ, Hoover DR, et al. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 2009; 101(1): 48–60.

Gunter MJ, Xie X, et al. Breast cancer risk in metabolically healthy but overweight postmeno- pausal women. Cancer Res. 2015; 75(2): 270-274.

Pal A, et al. PTEN mutations as a cause of constitutive insulin sensitivity and obesity. N Engl J Med. 2012; 367(11): 1002–1011.

Yang Y-X, et al. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology. 2004; 127(4): 1044–1050.

Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009; 52(9): 1766–1777.

Bowker SL, et al. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006 Feb; 29(2): 254–258.

Menke A, et al. Prevalence of and trends in diabetes among adults in the United States, 1988– 2012. JAMA. 2015; 314(10): 1021–1029.

Garber AJ, et al. Diagnosis and management of prediabetes in the continuum of hyperglyce- mia—when do the risks of diabetes begin? ACE /AACE Consensus Statement. Endocrine Pra- ctice. 2008 Oct; 14(7). Available from: https://www.aace.com/ files/prediabetesconsensus. pdf. Accessed 2017 Jun 6.

Fauber J, et al. The slippery slope: a bittersweet diabetes economy. Medpage Today. 2014 Dec

21. Available from: http://www.medpagetoday.com/Cardiology/Diabetes/49227. Accessed 2017 Jun 6.

American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 2013 Apr; 36(4): 1033–1046.

Palmer E. The top 10 best-selling diabetes drugs of 2013. Fierce Pharma. 2014 Jun 17. Available from: http://www.fiercepharma.com/pharma/top-10-best-sellingdiabetes- dru- gs-of-2013. Accessed 2017 Jun 6.

Based on data from Bianchi C, Del Prato S. Looking for new pharmacological treatments for type 2 diabetes. Diabetes Voice. 2011 Jun; 56: 28–31. Available from:https://www.idf. org/e-library/diabetes-voice/issues/28-june-2011.html?layout=article&aid=65. Accessed 2017 Jun 14.

The ACCOR D Study Group. Effects of intensive glucose lowering in type 2 diabetes.N Engl J Med. 2008; 358(24); 24: 2545–2559.

Centers for Disease Control and Prevention. Age-adjusted percentage of adults with diabetes using diabetes medication, by type of medication, United States,1997–2011. 2012 Nov 20. Available from: http://www.cdc.gov/diabetes/statistics/ meduse/fig2.htm. Accessed 2017 Jun 6.

Holman RR, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008 Oct; 359(15): 1577–1589.

Pantalone KM, et al. Increase in overall mortality risk in patients with type 2 diabetes re- ceiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis. Diabetes Obes Metab. 2012; 14(9): 803–809.

Tzoulaki I. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs. BMJ. 2009; 339: b4731. 12. Simpson SH, et al. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes melli- tus: a population-based cohort study. CMAJ. 2006; 174(2): 169–174.

Hong J, et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care. 2013 May; 36(5): 1304– 1311.

Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007; 356(24): 2457–2471.

Rosen CL. The rosiglitazone story—lessons from an FDA Advisory Committee Meeting. N Engl J Med. 2007; 357: 844–846.

Rosen CL. Revisiting the rosiglitazone story—lessons learned. N Engl J Med. 2010; 363(9): 803–806.

Tuccori M, et al. Pioglitazone use and risk of bladder cancer: population based cohort study. BMJ. 2016; 352: i1541.

Scirica BM, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013 Oct 3; 369(14): 1317–1326.

Green JB, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015 Jul 16; 373(3): 232–242.

The world’s top selling diabetes drugs. Pharmaceutical-technology.com. 2016 Mart 30. Available from: http://www.pharmaceutical-technology.com/features/featurethe-worl- ds-top-selling-diabetes-drugs-4852441/. Accessed 2017 Jan 31.

Rosenstock J, et al. Dual add-on therapy in type 2 diabetes poorly controlled withmetformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition ver- sus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care. 2015 Mar; 38(3): 376-383.

Chilton RC, et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab. 2015 Dec; 17(12): 1180-1193.

Zinman B, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373(22): 2117–2128.

Wanner C, et al. Empaglifozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016 Jul 28; 375(4): 323–334.

Blonde L, et al. Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgrad Med. 2016 May; 128(4): 371–380. doi: 10.1080/00325481.2016.1169894. Accessed 2017 Jun 6.

Wall JK. Analyst: Lilly’s Jardiance diabetes pill could be a $6 billion-a-year blockbuster. In- dianapolis Business Journal. 2015 Sep 21. Available from: http://www.ibj. com/blogs/12- the-dose/post/54957-analyst-lillys-jardiance-diabetes-pill-couldbe- a-6-billion-a-year-blo- ckbuster. Accessed 2017 Jun 6.

Chiasson JL, et al. Acarbose treatment and the risk of cardiovascular disease and hypertensi- on in patients with impaired glucose tolerance. JAMA. 2003; 290(4): 486-494.

Marso SP et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016; 375(4): 311–322.

Erpeldinger S, et al. Efficacy and safety of insulin in type 2 diabetes: meta-analysis of ran- domised controlled trials. BMC Endocr Disord. 2016; 16(1): 39. 30. Palmer SC, et al. Com- parison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes. A meta-analysis. JAMA. 2016; 316(3): 313–324.

Rodríguez-Gutiérrez R, Montori VM. Glycemic control for patients with type 2 diabetes mel- litus: our evolving faith in the face of evidence. Circulation. 2016; 9(5): 504-512.

Reversing type 2 diabetes starts with ignoring the guidelines. TEDxPerdueU. https://www. youtube.com/watch?v=da1vvigy5tQ. Accessed 2017 Jun 14.

Hallberg S, Hamdy O. Before you spend $26,000 on weight loss surgery, do this. The New York Times https://www.nytimes.com/2016/09/11/opinion/sunday/ before-you-spend- 26000-on-weight-loss-surgery-do-this.html?_r=0. Accessed 2017 Jun 14.

Kolata G. Diabetes and your diet: the low-carb debate. The New York Times. 2016 Sep 16. Available from: http://www.nytimes.com/2016/09/16/health/type-2-diabetes- low-carb- diet.html. Accessed 2017 Jun 6.

Nutrition recommendations and interventions for diabetes: a position statement of the Ame- rican Diabetes Association. Diabetes Care. 2008; 31(Suppl 1): S61–S78.

TO DAY Study Group. A clinical trial to maintain glycemic control in youth with type 2 diabe- tes. N Engl J Med. 2012; 366(24): 2247–2256.

Hu FB, et al. Dietary fat intake and the risk of coronary heart disease in women. N Engl J Med. 1997; 337(21): 1491–1499.

Howard BV, Van Horn L, et al. Low-fat dietary pattern and risk of cardiovascular disease: the Women’s Health Initiative Randomized Controlled Dietary Modification Trial. JAMA. 2006 Feb 8; 295(6): 655–666.

Howard BV, Manson JE, et al. Low-fat dietary pattern and weight change over 7 years: the Women’s Health Initiative Dietary Modification Trial. JAMA. 2006 Jan 4; 295(1): 39–49.

Oglesby P, et al. A longitudinal study of coronary heart disease. Circulation. 1963; 28: 20–31; Morris JN, et al. Diet and heart: a postscript. BMJ. 1977; 2(6098): 1307–1314; Yano K, et al. Dietary intake and the risk of coronary heart disease in Japanese men living in Hawaii. Am J Clin Nutr. 1978; 31(7): 1270–1279; Garcia- Palmieri MR, et al. Relationship of dietary intake to subsequent coronary heart disease incidence: The Puerto Rico Heart Health Program. Am J Clin Nutr. 1980; 33(8): 1818–1827; Shekelle RB, et al. Diet, serum cholesterol, and death from coronary disease: the Western Electric Study. N Engl J Med. 1981; 304(2): 65–70.

Mente A, et al. A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease. Arch Intern Med. 2009; 169(7): 659–669.

Wing R, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013; 369(2): 145–154.

Park A. Where dietary-fat guidelines went wrong. Time. 2015 Feb 9. Available from: http:// time.com/3702058/dietary-guidelines-fat-wrong/. Accessed 2017 Jun 6.

Booth FW, et al. Waging war on physical inactivity: using modern molecular ammunition aga- inst an ancient enemy. J Appl Physiol 2002; 93(1): 3–30. 14. O’Gorman DJ, Krook A. Exercise and the treatment of diabetes and obesity. Med Clin N Am. 2011; 95(5): 953–969.

O’Gorman DJ, Karlsson HKR, et al. Exercise training increases insulin-stimulated glucose disposal and GLUT4 (SLC2A4) protein content in patients with type 2 diabetes. Diabetologia. 2006; 49(12): 2983–2992.

Boulé NG, et al. Effects of exercise on glycemic control and body mass in type 2 diabetes mel- litus. JAMA. 2001; 286(10): 1218–1227.

Moore T. Experts urge surgery to cure type-2 diabetes. SkyNews. 2016 May 24. Available from: http://news.sky.com/story/experts-urge-surgery-to-cure-type-2- diabetes-10293295. Ac- cessed 2017 Jun 6.

Moshiri M, et al. Evolution of bariatric surgery: a historical perspective. Am J Roentgenol. 2013 Jul; 201(1): W40–48.

Rubino F. Medical research: Time to think differently about diabetes. Nature. 2016 May 24. Available from: http://www.nature.com/news/medical-research-timeto-think-differentl- y-about-diabetes-1.19955. Accessed 2017 Jun 6.

Kolata G. After weight-loss surgery, a year of joys and disappointments. The New York Ti- mes. 2016 Dec 27. Available from: https://www.nytimes.com/2016/12/27/ health/bariat- ric-surgery.html. Accessed 2017 Jun 6.

Keidar A, et al. Long-term metabolic effects of laparoscopic sleeve gastrectomy. JAMA Surg. 2015 Nov; 150(11): 1051–1057.

Based on data from Schauer PR, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012 Apr 26; 366(17): 1567–1576.

Schauer PR, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012 Apr 26; 366(17): 1567–1576.

Inge TH, et al. Weight loss and health status 3 years after bariatric surgery in adolescents. N Engl J Med. 2016; 374(2): 113–123.

Pories WJ, et al. Surgical treatment of obesity and its effect on diabetes: 10-y follow-up. Am J Clin Nutr. 1992 Feb; 55(2 Suppl): 582S–585S.

American Diabetes Association. Consensus from diabetes organizations worldwide: me- tabolic surgery recognized as a standard treatment option for type 2 diabetes. 2016 May

Available from: http://www.diabetes.org/newsroom/ press-releases/2016/consen- sus-from-diabetes-organizations-worldwide-metabolic-surgery-recognized-as-a-stan- dard-treatment-option-for-type-2-diabetes. html. Accessed 2017 Jun 6.

Klein S, et al. Absence of an effect of liposuction on insulin action and risk factors for coro- nary heart disease. N Engl J Med. 2004; 350(25): 2549–2557.

Hallberg S, Hamdy O. Before you spend $26,000 on weight-loss surgery, do this. The New York Times. 2016 Sep 10. Available from: https://www.nytimes.com/ 2016/09/11/opinion/ sunday/before-you-spend-26000-on-weight-loss-surgerydo- this.html?_r=0. Accessed 2017 Jun 6.

Knapton S. Obese three-year-old becomes youngest child diagnosed with Type 2 diabetes. The Telegraph. 2015 Sep 17. Available from: http://www.telegraph.co.uk/ news/health/ news/11869249/Obese-three-year-old-becomes-youngest-child-diagnosed-with-Ty- pe-2-diabetes.html. Accessed 2017 Jun 6.

World Health Organization. Global report on diabetes. 2016. Available from: http://www. who.int/diabetes/global-report/en/. Accessed 2017 Jun 6.

American Diabetes Association. Standards of medical care in diabetes 2016. Diabetes Care. 2016 Jan; 39(Suppl 1): S25–26.

American Diabetes Association. Nutrition recommendations and interventions for diabe- tes. A position statement of the American Diabetes Association. Diabetes Care. 2008 Jan; 31(Suppl 1): S61–S78.

De Lorgeril M, et al. Mediterranean diet, traditional risk factors, and the rate of cardiovas- cular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation. 1999; 99(6): 779–785.

Mozzafarian D, Rimm EB, et al. Dietary fats, carbohydrate, and progression of coronary athe- rosclerosis in postmenopausal women. Am J Clin Nutr. 2004; 80(5): 1175–1184.

Estruch R, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013 Apr 4; 368(14): 1279–1290.

Hoenselaar R. Further response from Hoenselaar. Br J Nutr. 2012 Sep; 108(5): 939–942.

Siri-Tarino PW, et al. Meta-analysis of prospective cohort studies evaluating the association of saturated fat with cardiovascular disease. Am J Clin Nutr. 2010; 91(3); 535–546.

Kagan A, et al. Dietary and other risk factors for stroke in Hawaiian Japanese men. 1985; 16(3): 390–396; Gillman MW, et al. Inverse association of dietary fat with development of ischemic stroke in men. JAMA. 1997 Dec 24–31; 278(24): 2145–2150.

Based on data from Yamagishi K, et al. Dietary intake of saturated fatty acids and mortality from cardiovascular diseases in Japanese: the Japan Collaborative Cohort Study for Evalua- tion of Cancer Risk (JACC ) study. Am J Clin Nutr. 2009 Oct; 92(4): 759-765. Available from: doi:10.3945/ajcn.2009.29146. Accessed 2017 Jun 6.

Hu FB, Stampfer MJ, et al. Frequent nut consumption and risk of coronary heart disease in women: prospective cohort study. BMJ. 1998; 317(7169): 1341–1345.

Burr ML. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarcti- on: diet and reinfarction trial (DART ). Lancet. 1989 Sep 30; 2(8666): 757–756.

Mozaffarian D, Cao H, et al. Trans-palmitoleic acid, metabolic risk factors, and new-onset di- abetes in US adults. Ann Intern Med. 2010 December 21; 153(12): 790–799.

Liu L, et al. Egg consumption and risk of coronary heart disease and stroke: dose-response meta-analysis of prospective cohort studies. BMJ. 2013 Jan 7; 346: e8539.

Shin JY, et al. Egg consumption in relation to risk of cardiovascular disease and diabetes. Am J Clin Nutr. 2013 July; 98(1): 146–159.

Masharani U, et al. Metabolic and physiologic effects from consuming a hunter-gatherer (Pa- leolithic)-type diet in type 2 diabetes. European J Clin Nutr. 2105;69(8): 944–948.

Hu FB, Manson JE, et al. Types of dietary fat and risk of coronary heart disease: a critical review. J Am Coll Nutr. 2001; 20(1): 5–19.

Liu S, et al. A prospective study of dietary glycemic load, carbohydrate intake, and risk of coronary heart disease in US women. Am J Clin Nutr. 2000 Jun; 71(6): 1455–1461.

Based on data from Liu S, et al. A prospective study of dietary glycemic load, carbohydrate intake, and risk of coronary heart disease in US women. Am J Clin Nutr. 2000 Jun; 71(6): 1455–1461.

Ajala O, et al. Systematic review and meta-analysis of different dietary approaches to the management of type 2 diabetes. Am J Clin Nutr. 2013; 97(3): 505–516.

Goday A, et al. Short-term safety, tolerability and efficacy of a very low-calorieketogenic diet interventional weight loss program versus hypocaloric diet in patients with type 2 diabetes mellitus. Nutrition & Diabetes. 2016; 6: e230.

Based on data from Cohen E, et al. Statistical review of US macronutrient consumption data, 1965–2011: Americans have been following dietary guidelines, coincident with the rise in obesity. Nutrition. 2015 May; 31(5): 727–732.

Centers for Disease Control and Prevention. Trends in intake of energy and macronutrients— United States: 1971 to 2000. JAMA. 2004; 291: 1193–1194.

Villegas R, et al. Prospective study of dietary carbohydrates, glycemic index, glycemic load, and incidence of type 2 diabetes mellitus in middle-aged Chinese women. Arch Intern Med. 2007 Nov 26; 167(21): 2310–2316.

Based on data from Harvard Medical School. Glycemic index and glycemic load for 100+ foo- ds: measuring carbohydrate effects can help glucose management. Harvard Health Publicati- ons [Internet]. February 2015. Updated 27 August 2015. Available from: http://www.health. harvard.edu/diseases-and-conditions/glycemic_ index_and_glycemic_load_for_100_foods. Accessed 2017 Jun 6.

Trowell HC, Burkitt DP. Western diseases: their emergence and prevention. Boston: Harvard University Press; 1981.

Lindeberg S, et al. Low serum insulin in traditional Pacific Islanders—the Kitava study. Meta- bolism. 1999 Oct; 48(10): 1216–1219.

Giugliano D, et al. Effects of a Mediterranean-style diet on the need for antihyperglycemic drug therapy in patients with newly diagnosed type 2 diabetes. Ann Int Med. 2009 Sep 1; 151(5): 306–313.

Feinman RD, et al. Dietary carbohydrate restriction as the first approach in diabetes manage- ment: Critical review and evidence base. Nutrition. 2015; 31(1): 1–13.

Banting W. Letter on Corpulence. Available from: http://www.thefitblog.net/ ebooks/Lette- rOnCorpulence/LetteronCorpulence.pdf. Accessed 2017 Jun 6.

Unwin DJ, et al. It’s the glycaemic response to, not the carbohydrate content of food that matters in diabetes and obesity: The glycaemic index revisited. Journal of Insulin Resistan- ce. 2016; 1(1). Available from: http://www.insulinresistance. org/index.php/jir/article/ view/8. Accessed 2017 Jun 14. Used with permission.

Hughes T, Davies M. Thousands of diabetics adopt high-protein low-carb diet in backlash against official NHS eating plan. The Daily Mail. 2016 May 31. http:// www.dailymail.co.uk/ news/article-3617076/Diabetes-patients-defy-NHS-Thousands- rebel-against-guideli- nes-controlling-condition-diet-low-carbohydrates. html. Accessed 2017 Jun 12.

Hamdy O. Nutrition revolution—the end of the high carbohydrates era for diabetes preventi- on and management. US Endocrinology. 2014; 10(2): 103–104.

Third national health and nutrition examination survey. Medscape J Med. 2008;10(7): 160.

Siri-Tarino PW, et al., Meta-analysis of prospective cohort studies evaluating the association of saturated fat with cardiovascular disease. Am J Clin Nutr. 2010; 91(3): 535–546; Estruch R, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013 Apr 4; 368(14): 1279–1290.

Lingvay I. Rapid improvement of diabetes after gastric bypass surgery: is it the diet or the surgery? Diabetes Care. 2013 Sep; 36(9): 2741–2747.

American Diabetes Association. Standards of medical care in diabetes 2016. Diabetes Care. 2016; 39(Suppl 1): S48.

Fildes A, et al. Probability of an obese person attaining normal body weight: cohort study using electronic health records. Am J Public Health. 2015; 105(9): e54–e59.

Harvie MN, et al. The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women. Int J Obes (Lond). 2011 May; 35(5): 714–727.

Based on data from Harvie MN, et al. The effect of intermittent or continuous energy restric- tion on weight loss and metabolic disease risk markers: A randomized trial in young overwe- ight women. Int J Obes. 2011 May; 35(5): 714–727.

Catenacci VA, et al. A randomized pilot study comparing zero-calorie alternate-day fasting to daily caloric restriction in adults with obesity. Obesity (Silver Spring). 2016 Sep; 24(9): 1874–1883.

Johannsen DL, et al. Metabolic slowing with massive weight loss despite preservation of fat-free mass. J Clin Endocrinol Metab. 2012 Jul; 97(7): 2489–2496.

Best fast weight-loss diets. U.S. News & World Report. Available from: http://health.usnews. com/best-diet/best-fast-weight-loss-diets. Accessed 2017 Feb 3.

Callahan M. “We’re all fat again”: More “Biggest Loser” contestants reveal secrets. New York Post. 2015 Jan 25. Available from: http://nypost.com/2015/01/25/wereall-fat-again-mo- re-biggest-loser-contestants-reveal-secrets/. Accessed 2017 Jun 6.

Fothergill E, et al. Persistent metabolic adaptation 6 years after “The Biggest Loser”competi- tion. Obesity. 2016; 24(8): 1612–1619.

Keys A, et al. The Biology of Human Starvation. 2 vols. St. Paul, MN: University ofMinnesota Press; 1950.

Zauner C, et al. Resting energy expenditure in short-term starvation is increasedas a result of an increase in serum norepinephrine. Am J Clin Nutr. 2000; 71(6):1511–1515.

Heilbronn LK, et al. Alternate-day fasting in nonobese subjects: effects on body weight, body composition, and energy metabolism. Am J Clin Nutr. 2005; 81(1): 69–73.

Based on data from Zauner C. Resting energy expenditure in short-term starvation is inc- reased as a result of an increase in serum norepinephrine. Am J Clin Nutr. 2000 Jun; 71(6): 1511–1515.

Nuttall FQ, et al. Comparison of a carbohydrate-free diet vs. fasting on plasma glucose, insulin and glucagon in type 2 diabetes. Metabolism. 2015 Feb; 64(2): 253–262.

Jackson I, et al. Effect of fasting on glucose and insulin metabolism of obese patients. Lancet. 1969; 293(7589): 285–287.

Li G, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: A 20-year follow-up study. Lancet. 2008; 371(9626): 1783–1789.

Wareham NJ. The long-term benefits of lifestyle interventions for prevention of diabetes. Lancet Diabetes & Endocrinology. 2014 Jun; 2(6): 441—442.

Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346(6): 393–403.

Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009; 374(9702): 1677–1686.

Ramachandran A, et al. The Indian Diabetes Prevention Programme shows that lifestyle mo- dification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006; 49(2): 289–297.

Tuomilehto J, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among sub- jects with impaired glucose tolerance. N Engl J Med. 2001; 344(18): 1343–1350.

Kosaka K, et al. Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Res Clin Pract. 2005; 67(2): 152–162.